Join us at the Merck Technology Symposium 2019. We work with our Merck partners to bring high-quality biological specimens and value-added services.
Stop by our table to meet with our business development team discuss how BioIVT can work collaboratively with you in your drug discovery development program. And as the world’s premier supplier of ADME-toxicology model systems, including HEPATOPAC®, LIVERPOOL® hepatocytes and subcellular fractions, we enable scientists to better understand the pharmacokinetics and drug metabolism of newly discovered compounds and the effects on disease processes.
Sept. 23, 1:15pm – 2:30pm and Sept. 24, 1:00pm – 2:15pm
Demonstration of hepatocyte-targeted siRNA transfection and gene silencing in the micro-patterned hepatocyte co-culture system (HEPATOPAC)
Presenter: Miranda Yang, Ph.D., Senior Scientist, BioIVT
The HEPATOPAC® model, an in vitro bioengineered co-culture of primary hepatocytes and fibroblasts, has demonstrated invaluable utility for liver-based safety, metabolism and efficacy evaluation for small molecule drug candidates due to its longevity and close resemblance to the in vivo liver. Here, we identify a method to specifically deliver small-interfering RNAs (siRNA) into the hepatocytes in the HEPATOPAC® co-cultures by using a commercially available, non-liposomal transfection reagent that targets hepatocytes (PromoFectin-Hepatocyte).
By combining our technical expertise, exceptional customer service, and unparalleled access to biological specimens and hepatic products, BioIVT serves the research community as a trusted partner in ELEVATING SCIENCE®.